UNSPSC 51102823: Bacitracin/polymyxin b/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

UNSPSC 51102823 Bacitracin/polymyxin b/pramoxine is a Commodity code that encompasses topical antibiotic and anesthetic pharmaceutical products, though recent state and local solicitations tagged to this code show a broader purchasing pattern focused on pharmaceutical procurement and medical supplies rather than this specific antibiotic combination alone. State and local buyers using this code include county health departments, city fire and rescue services, and state health agencies coordinating multistate cooperative purchasing. The solicitations reflect demand for medical and first aid supplies, naloxone and drug deactivation systems, generic pharmaceuticals through authorized wholesalers, and direct-to-manufacturer pharmacy initiatives, indicating that the code captures a range of pharmaceutical and emergency medical procurement across different government service lines.

Recent activity spans Florida, Texas, Minnesota, and Oregon through four representative solicitations. Seminole County, Florida (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries and a two-year initial term plus one-year renewal option. The City of Tampa (IFB 26P00145, due March 13, 2026) issued a $700,000 sheltered-market procurement for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with a 5 percent bid discount for certified Small Local Business Enterprises. The Texas Health and Human Services Commission (RFI HHS0017013, due April 3, 2026) posted an exploratory Request for Information on direct-to-manufacturer prescription programs to inform future procurement strategy. The Minnesota Department of Administration, administering the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026), solicited multiple contract awards for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with products required to be available by May 15, 2026 and agreements effective July 1, 2026; evaluation weighted pricing competitiveness at 75 percent and required vendors to maintain compliance with cGMP and DSCSA standards.